Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 11, 2026, 3:29 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–41 of 17 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Ecp Clear all
Completed Phase 2 Interventional Results available

Extracorporeal Photopheresis and Low Dose Aldesleukin in Treating Patients With Steroid Refractory Chronic Graft-Versus-Host Disease

NCT03007238
View directory record Official record
Conditions
Chronic Graft Versus Host Disease
Interventions
Aldesleukin, Extracorporeal Photopheresis, Laboratory Biomarker Analysis, Quality-of-Life Assessment
Biological · Procedure · Other
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Apr 7, 2024 · Synced Sep 11, 2026, 3:29 AM EDT
Completed Phase 2 Interventional Results available

A Trial of Extracorporeal Photopheresis, Pentostatin, and Total Body Irradiation in Patients Undergoing Reduced Intensity Allogeneic Stem Cell Transplantation for the Treatment of Malignancies

NCT00402714
View directory record Official record
Conditions
Hematologic Malignancies
Interventions
extracorporeal photopheresis, Pentostatin, Total Body Irradiation
Procedure · Drug · Radiation
Lead sponsor
Yale University
Other
Eligibility
18 Years to 75 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
3
States / cities
New Haven, Connecticut • Boston, Massachusetts • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jan 17, 2017 · Synced Sep 11, 2026, 3:29 AM EDT
Terminated Phase 2 Interventional Results available

Itacitinib (INCB039110) and Extracorporeal Photopheresis (ECP) for First-Line Treatment in Chronic GVHD

NCT04446182
View directory record Official record
Conditions
Chronic Graft-versus-host-disease
Interventions
Itacitinib, Extracorporeal Photopheresis (ECP)
Drug · Device
Lead sponsor
University of Utah
Other
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Jan 21, 2024 · Synced Sep 11, 2026, 3:29 AM EDT
Recruiting Not applicable Interventional

External Post-Operative Skull Prosthesis to Prevent Sunken Flap Syndrome in Craniectomy Patients

NCT06899711
View directory record Official record
Conditions
Craniectomy, Trephined Syndrome, Traumatic Brain Injury (TBI) Patients, Ischemic Stroke
Interventions
External Cranial Prosthesis
Device
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
2
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated May 10, 2026 · Synced Sep 11, 2026, 3:29 AM EDT
Terminated Phase 3 Interventional Results available

Methoxsalen and Extracorporeal Photopheresis (ECP) for the Treatment of Pediatric Participants With Steroid Refractory Acute Graft Versus Host Disease

NCT02524847
View directory record Official record
Conditions
Steroid Refractory Acute Graft Versus Host Disease
Interventions
Methoxsalen, Extracorporeal Photopheresis (ECP)
Drug · Procedure
Lead sponsor
Therakos, Inc., a Mallinckrodt Company
Industry
Eligibility
1 Year to 21 Years
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
17
States / cities
Phoenix, Arizona • Los Angeles, California • New Haven, Connecticut + 13 more
Source: ClinicalTrials.gov public record
Updated Sep 10, 2020 · Synced Sep 11, 2026, 3:29 AM EDT
Terminated No phase listed Observational

Prospective Outcomes of Second-Line Therapy in Acute Graft-Versus-Host Study Including ECP (POSTAGE)

NCT02151539
View directory record Official record
Conditions
Graft Versus Host Disease
Interventions
medical chart review, quality-of-life assessment
Other
Lead sponsor
Vanderbilt-Ingram Cancer Center
Other
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
4
States / cities
Scottsdale, Arizona • Rochester, Minnesota • Cleveland, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 16, 2019 · Synced Sep 11, 2026, 3:29 AM EDT
Terminated Phase 2 Interventional Results available

Biomarkers in Acute Graft-Versus-Host Disease and Extracorporeal Photopheresis Added to Investigator Chosen Therapies of Steroid Refractory Acute GVHD

NCT02322190
View directory record Official record
Conditions
Chronic Graft vs. Host Disease, Graft vs Host Disease, Graft-Versus-Host Disease
Interventions
Extracorporeal Photopheresis (ECP), Methoxsalen
Procedure · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 99 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 11, 2020 · Synced Sep 11, 2026, 3:29 AM EDT
Completed Not applicable Interventional Results available

Wave Crossover ECP Study for Simplified Therapy

NCT06571370
View directory record Official record
Conditions
Chronic Stable Angina, Refractory Angina
Interventions
External Counterpulsation
Device
Lead sponsor
Pression
Industry
Eligibility
35 Years and older
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Monroe, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 6, 2026 · Synced Sep 11, 2026, 3:29 AM EDT
Completed Phase 4 Interventional

Photopheresis as an Interventional Therapy for the Treatment of CTCL (Cutaneous T-Cell Lymphoma, Mycosis Fungoides) Stage 1A, 1B, 2A

NCT00221039
View directory record Official record
Conditions
Cutaneous T Cell Lymphoma, Mycosis Fungoides
Interventions
Methoxsalen+ECP
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2011
U.S. locations
7
States / cities
Chicago, Illinois • Boston, Massachusetts • Minneapolis, Minnesota + 4 more
Source: ClinicalTrials.gov public record
Updated Aug 16, 2018 · Synced Sep 11, 2026, 3:29 AM EDT
Completed Phase 1 Interventional Results available

Safety Study of External Counterpulsation as a Treatment for Acute Ischemic Stroke

NCT00983749
View directory record Official record
Conditions
Stroke
Interventions
Full-pressure ECP, Sham-pressure ECP
Device
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years to 85 Years
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
3
States / cities
Birmingham, Alabama • Los Angeles, California • San Diego, California
Source: ClinicalTrials.gov public record
Updated Jun 27, 2016 · Synced Sep 11, 2026, 3:29 AM EDT
Terminated Not applicable Interventional Results available

Open-Label Study to Evaluate the Efficacy of ECP in Secondary Progressive Multiple Sclerosis

NCT02296346
View directory record Official record
Conditions
Secondary Progressive Multiple Sclerosis
Interventions
SoluMedrol, Extracorporeal Photopheresis
Drug · Device
Lead sponsor
University of Utah
Other
Eligibility
18 Years to 75 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Aug 13, 2019 · Synced Sep 11, 2026, 3:29 AM EDT
Terminated Phase 1Phase 2 Interventional

Mogamulizumab and Extracorporeal Photopheresis for the Treatment of Sezary Syndrome or Mycosis Fungoides

NCT04676087
View directory record Official record
Conditions
Mycosis Fungoides, Primary Cutaneous T-Cell Non-Hodgkin Lymphoma, Sezary Syndrome
Interventions
Extracorporeal Photopheresis, Mogamulizumab, Quality-of-Life Assessment
Procedure · Biological · Other
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Aug 12, 2024 · Synced Sep 11, 2026, 3:29 AM EDT
Completed Phase 1Phase 2 Interventional

Reduced Intensity Transplant Using Extracorporeal Photopheresis

NCT00179790
View directory record Official record
Conditions
Leukemia, Cancer
Interventions
Extracorporeal Photopheresis
Procedure
Lead sponsor
Ann & Robert H Lurie Children's Hospital of Chicago
Other
Eligibility
Not listed
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2015
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Mar 5, 2017 · Synced Sep 11, 2026, 3:29 AM EDT
Completed Early Phase 1 Interventional

Test Extracorporeal Photopheresis (ECP) Treatment Before/After Allogeneic Bone Marrow Transplant (BMT) or Peripheral Blood Stem Cell (PBSC) Transplant to Prevent Graft Versus Host Disease

NCT01174940
View directory record Official record
Conditions
Stem Cell Leukemia of Unclear Lineage, Graft Versus Host Disease
Interventions
extracorporeal photopheresis
Drug
Lead sponsor
University of Kansas Medical Center
Other
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
1
States / cities
Kansas City, Kansas
Source: ClinicalTrials.gov public record
Updated Jan 8, 2017 · Synced Sep 11, 2026, 3:29 AM EDT
Recruiting No phase listed Observational

Extracorporeal Photopheresis in Sezary Syndrome

NCT05157581
View directory record Official record
Conditions
Sezary Syndrome
Interventions
Extracorporeal photopheresis (ECP), Methoxsalen Injection
Device · Drug
Lead sponsor
Oleg E. Akilov, MD, PhD
Other
Eligibility
18 Years to 100 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
3
States / cities
Atlanta, Georgia • Baltimore, Maryland • Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 29, 2025 · Synced Sep 11, 2026, 3:29 AM EDT
Enrolling by invitation Not applicable Interventional

Impella ECP Study (ECP Study) and Impella ECP Continued Access Protocol

NCT05334784
View directory record Official record
Conditions
High-Risk Percutaneous Coronary Intervention
Interventions
Impella ECP
Device
Lead sponsor
Abiomed Inc.
Industry
Eligibility
18 Years to 90 Years
Enrollment
856 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
32
States / cities
Phoenix, Arizona • Tucson, Arizona • Little Rock, Arkansas + 27 more
Source: ClinicalTrials.gov public record
Updated Mar 4, 2026 · Synced Sep 11, 2026, 3:29 AM EDT
Active, not recruiting Not applicable Interventional

Impella ECP Early Feasibility Study

NCT04477603
View directory record Official record
Conditions
High-risk Percutaneous Coronary Intervention
Interventions
Impella ECP
Device
Lead sponsor
Abiomed Inc.
Industry
Eligibility
18 Years to 90 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
5
States / cities
Boston, Massachusetts • Detroit, Michigan • Paramus, New Jersey + 1 more
Source: ClinicalTrials.gov public record
Updated Apr 13, 2026 · Synced Sep 11, 2026, 3:29 AM EDT